Laboratory Assessment of Gastrointestinal Cancer Patients Pre and Post Chemotherapy

Main Article Content

Rajini Kurup
Latoya Gooding
Cecil Boston
Shane Blair
Niromanie Ramsarup
Yeama Singh


Aims: Chemotherapy-induced neutropenia is a common side effect in cancer patients. Other hematopoietic lineages are also decreased in cancer patient. Altered laboratory parameters would prevent patients from chemotherapy. Thus this study identified the significance of blood parameters during chemotherapy among Gastrointestinal (GI) cancer patients.

Study Design: Laboratory based descriptive study.

Place and Duration of Study: Cancer Institute, Georgetown Public Hospital Cooperation, Guyana between 2011 to 2015.

Methodology: A total of 47 patients were included in the study who were diagnosed with GI cancer. Mean±SD was used to measure biochemical and hematological means.

Results: Mean of the patients age was 59.9. Most prevalent GI cancer was of colon (44.7), followed by rectum (12.8). Cancer of maxilla, oesophagus, gall bladder, liver and rectum all had almost the same prevalence (2.1). Most patients used Fluorouracil (74.5%) and Oxaliplatin (72.3). And 42.6% of the patients underwent radiation. There was a variation noted in the values of the hematological and biochemical parameters.

Conclusion: The cancer patients showed a huge variations in the biochemical and hematological parameters.

Chemotherapy, laboratory assessments, Guyana

Article Details

How to Cite
Kurup, R., Gooding, L., Boston, C., Blair, S., Ramsarup, N., & Singh, Y. (2020). Laboratory Assessment of Gastrointestinal Cancer Patients Pre and Post Chemotherapy. Asian Oncology Research Journal, 3(2), 1-6. Retrieved from
Original Research Article


Rebecca Siegel, Jiemin Ma, Zhaohui Zou, and Ahmedin Jemal. Cancer statistics, 2014. CA: A Cancer Journal for Clinicians. 2014;64(1):9–29.

Berci G, Forde KA. History of endoscopy. Surgical endoscopy. 2000;14(1):5–15.

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

CDC; 2016.

Lynn JJ, Chen KF, Weng YM, Chiu TF. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department. Hematol Oncol. 2013;31(4): 189–196.

Del Conte G, Sessa C, von Moos R, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer. 2014;111(4):651–659.

Hong J, Woo HS, Kim H, et al. Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy. Cancer Sci. 2014;105(12):1569–1575.

Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91(12):2214-21.

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106 (10):2258–2266.

Shaikh AJ, Bawany SA, Masood N, et al. Incidence and impact of base¬line electrolyte abnormalities in patients admitted with chemotherapy induced febrile neutropenia. J Cancer. 2011;2:62–66.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352 (10):1011–23.

GLOBOCAN. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide; 2012.

Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123–134.

Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444.

Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck. 2016;38:1074–1084.

Mao Y, Qu Q, Chen XS, Huang O, Wu JY, Shen KW. The prognostic value of tumor-infiltrating lymphocytes in breast cancer: A systematic review and meta-analysis. PLoS One. 2016;11:13.

Dale DC. Neutropenia. In: Herman NW. (ed.) Encyclopedia of Life Sciences. Chichester John Wiley & Son's, Ltd. 2005; 10-32.

Frey R, Granger J. Neutropenia. In: Thackery E. (ed) The gale encyclopedia of cancer, Detroit: Gale Group. 2002;770-773.

Linker CA. Blood. In: Tiernery LM., McPhee SJ. Papadakis MA. (eds.) Current medical diagnosis and treatment. New York, Appleton & Lange. 2000;222-238.

Verstraete M, Vrhaeghe R, Peerlinck K, Boogaerts MA. Haematological disorders. In: Speight TM, Holford NH. (eds.) A very's Drug Treatment. Auckland, Adis Press. 1997;56-68.

Kimble-Koda MA, Young LY, Kardjan WA, Guglielmo BJ. Infections in neutropenic patients. In: Troy D. (eds.) Hand Book of Applied Therapeutics, Philadelphia, Lippincott Williams & Wilkins. 2002;203-241.

Cihan YB, Ozturk A, and Mutlu H. Relationship between prognosis and neutrophil: lymphocyte and platelet: Lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pacific Journal of Cancer Prevention. 2014;15(5):2061–2067.

Wei Y, Jiang YZ, and Qian WH. Prognostic role of NLR in urinary cancers: A meta-analysis. PLoS ONE. 2014;9(3).
[ID: e92079]

Li MX, Liu XM, Zhang XF, et al. Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. International Journal of Cancer. 2014;134(10):2403–2413.

Malietzis G, Giacometti M, Kennedy RH, Athanasiou T, Aziz O, Jenkins JT. The emerging role of neutrophil to lymphocyte ratio in determining colorectal cancer treatment outcomes: A systematic review and meta-analysis. Annals of Surgical Oncology. 2014;21(12):3938–3946.

Sun J, Chen X, Gao P, Song Y, Huang X et al. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A Systematic Review and Meta-Analysis; 2016.
[ID: 7862469]